Article Sidebar
Published:
Sep 8, 2015Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Evaluation of anti-cancer properties of pegylated ethosomal paclitaxel on human melanoma cell line SKMEL- 3
Abstract
Methods: Nanodrug was prepared by reverse phase evaporation technique. The characteristics of the nanoparticles were evaluated by a zetasizer and scanning electron microscopy (SEM). Drug loading and encapsulation efficiency as well as paclitaxel® release were determined spectrophotometerically at 227 nm while the cytotoxicity of the pegylated ethosomal nanoencapsulated Paclitaxel® was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay on SK-MEL-3 cell line.
Results: The mean diameter and zeta potential of drug-loaded pegylated ethosomal particles and blank pegylated ethosomes were 138.1 ± 2.7 nm and -13.1 mV, and 102.3 ± 2.1 nm and -19.2 mV, respectively, while drug loading and encapsulation efficiency were 2.82 ± 0.27 and 96 ± 1.27 %, respectively. The drug release pattern indicates that the half-life (t1/2) of the nanodrug was approximately twice that of the free drug for both static and dynamic release. Toxicological results indicate approx. 4.5-fold cytotoxicity against SK-MEL-3 cell line compared with the free drug.
Conclusion: This study shows that pegylated ethosomal Paclitaxel® is significantly considerably more toxic than the free drug on SK-MEL-3 cell line, thus making it an potential alternative to the standard therapy. It is, however, necessary to evaluate the nanoformulation in vivo.
